Arizona Department of Health Services, ADAP

Background: In April 2015, the ADHS ADAP Formulary Committee moved to add the latest, FDA[1] approved hepatitis C medications to the ADAP formulary without requiring a prior-authorization[2]. The medications added thus far include:

1. Harvoni (*ledipasvir-sofosbuvir*);
2. Sovaldi (*sofosbuvir*);
3. Daklinza (*daclatasvir*)
4. Zepatier (*elbasvir and grazoprevir*)
5. Epclusa (*sofosbuvir-velpatasvir*)
6. Mavyret (glecaprevir/pibrentasvir)

The addition of these medications to the ADAP Formulary has presented ADHS with a unique system in which to identify, manage and monitor co-infected HIV/HCV patients via collaborative partnerships with medical providers and clinics throughout the state.

Registry Purpose: The primary purpose of the *Arizona Department of Health Services*' (ADHS), AIDS Drug Assistance Program's (ADAP) HIV[3]/HCV[4] Therapeutic Registry is to establish a state-wide HIV/HCV co-infection patient registry that maintains key demographic and clinical data on HIV-positive patients receiving treatment for chronic hepatitis C antiviral therapy.

Registry Eligibility: ADAP clients over 18 years old that are co-infected with HIV/HCV.

Registry Data: Clinician offices will send key demographic and clinical information to the ADHS ADAP Office at least twice in/after the course of treatment.

BEFORE TREATMENT	
Patient Demographics	Patient Name, Sex, DOB, Race, Provider Name
Patient HCV Specifics	Date of Original Diagnosis, HCV Genotype and Subtype, HCV Viral Load Pre-Treatment (within 12 months of starting HCV treatment trial), Stage of Fibrosis (0-4), Presence of Cirrhosis (Yes/No, Compensated or Decompensated), Prior Treatment Regimens and Durations, Proposed Treatment Regimen
Patient Overall Health	BMI (before HCV Treatment), Active Injection Drug Use, Active EtoH use, Psychiatric Diagnosis

AFTER TREATMENT	
Patient Demographics	Patient Name, Sex, DOB, Race, Provider Name
Patient HCV Specifics	SVR-12 (HCV Viral Load 12 weeks after treatment completion), Total Duration of HCV Treatment Trial, Reason for Early Termination of HCV Treatment Trial (if applicable)
Patient Overall Health	BMI (after HCV treatment), Active Injection Drug Use, Active EtoH use, Psychiatric Diagnosis

Timeline: The HIV/HCV Therapeutic Registry will have a start date of August 3, 2015.

[1] FDA (U.S. Food and Drug Administration)
[2] Review of a medication prior to prescription payment
[3] HIV (Human Immunodeficiency Virus)
[4] HCV (Hepatitis C Virus)